Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc (OVID) is a biopharmaceutical innovator developing therapies for rare neurological disorders, with a focus on epilepsy and seizure-related conditions. This page serves as the definitive source for Ovid Therapeutics news, providing investors and stakeholders with timely updates on clinical developments and corporate milestones.
Access official press releases and curated news covering drug development progress, clinical trial results, strategic partnerships, and regulatory updates. Our repository ensures you stay informed about Ovid’s pipeline advancements, including novel candidates targeting Angelman syndrome, fragile X syndrome, and rare epileptic encephalopathies.
Key updates include progress reports on first-in-class therapies, collaborations with industry leaders like Takeda, and insights into Ovid’s scientific approach. Bookmark this page to monitor developments in neurological treatment innovation and make data-driven decisions with direct access to primary source materials.
Ovid Therapeutics (NASDAQ: OVID) presented results of a pre-clinical study comparing OV329 to vigabatrin (VGB) at the Epilepsy Pipeline Conference. The study found that OV329 did not accumulate in mouse retinas, eyes, or brains after 48 hours of continuous exposure, unlike VGB which showed ocular accumulation. OV329's unique properties, including potency, short half-life, and rapid tissue elimination, suggest a potentially differentiated ocular safety profile.
The study tested OV329 at 5 mg/kg/day versus VGB at 80 mg/kg/day. OV329 concentrations were undetectable in target tissues, while VGB accumulated preferentially in the retina and other tissues. Ovid is currently conducting a Phase 1 trial of OV329 in healthy volunteers, expected to complete in late 2024, evaluating safety and biomarkers for target engagement and clinical effect.
Ovid Therapeutics Inc. (NASDAQ: OVID) has promoted Meg Alexander to President and Chief Operating Officer (COO). This strategic move aims to strengthen the company's leadership and drive future growth in its mission to develop disease-halting neurotherapeutics for rare epilepsies and brain conditions.
Alexander, who joined Ovid in 2020, will oversee operations, R&D, program management, investor relations, commercial strategy, human resources, and corporate affairs. She brings extensive experience in the biopharmaceutical industry, having guided the launch of over 25 medicines and shaped major initiatives for leading companies.
The promotion is part of Ovid's strategy to advance its development pipeline, which includes novel ROCK2 inhibitors, KCC2 direct activators, and a GABA-aminotransferase inhibitor. This leadership change positions Ovid to capitalize on its scientific, development, and deal-making expertise to create value and impact the lives of those with intractable brain disorders.
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on rare epilepsies and brain conditions, has announced its participation in two major investor conferences this September. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET. Additionally, Ovid will engage in a fireside chat at the Cantor Global Healthcare Conference on September 17th at 1:55 p.m. ET.
Both events will be webcast live and can be accessed through the Events & Presentations section of Ovid's investor website. Archived replays will be available on the company's website following the live presentations, providing investors and interested parties with opportunities to stay informed about Ovid's latest developments and strategic outlook.
Ovid Therapeutics (NASDAQ: OVID) reported business updates and Q2 2024 financial results. Key highlights include:
- Appointment of Dr. Amanda Banks as Chief Development Officer
- Expansion of Scientific Advisory Board
- 43% workforce reduction and streamlined operations
- Strong financial position with $77.0 million in cash and marketable securities
- Advancement of OV888/GV101 to Phase 2 proof-of-concept study
- Anticipated completion of OV329 Phase 1 MAD study in H2 2024
- Suspension of OV329 IV program
- Planned regulatory submission for OV350 in H2 2024
Financial results show $169,000 in revenue, $20.7 million in operating expenses, and a net income of $8.5 million for Q2 2024. The company expects its cash runway to support operations through late H1 2026.
Ovid Therapeutics (NASDAQ: OVID) has appointed Dr. Amanda Banks as Chief Development Officer. Dr. Banks will oversee clinical development, medical, and regulatory affairs functions, as well as drive corporate development strategy. Her expertise in neurology, clinical strategy, and business development is expected to help Ovid unlock potential therapeutic opportunities in their ROCK2 inhibition and KCC2 direct activator platforms.
Dr. Banks brings a strong track record in business leadership and securing transformational partnerships. Her experience spans multiple therapeutic areas, including neurology, oncology, metabolic disorders, and infectious disease. Prior to joining Ovid, she co-founded and served as CEO of Blackfynn, a data platform company focused on accelerating therapeutics development for neurological diseases.
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company focused on improving lives affected by epilepsies and brain conditions, has announced its participation in two upcoming investor conferences in August 2024:
1. BTIG Virtual Biotechnology Conference: Ovid will engage in a fireside chat on Tuesday, August 6th at 10:00 a.m. ET.
2. 2024 Wedbush PacGrow Healthcare Conference: The company will participate in a panel discussion on Tuesday, August 13th at 10:15 a.m. ET.
Both events will be accessible via live webcasts through the Events & Presentations section of Ovid's website at investors.ovidrx.com. Archived replays will be available on the company's website following the live presentations.
Ovid Therapeutics (NASDAQ: OVID) has expanded its Scientific Advisory Board (SAB) with the appointment of leading neurologists, neuroscientists, and epileptologists. The expanded SAB will advise on the potential application of Ovid's compounds to broader brain disorders, focusing on conditions caused by hyperexcitability, neurovascular and neuro-inflammatory dysfunction.
Key appointments include Dr. Imad Najm of Cleveland Clinic, Dr. Raman Sankar of UCLA Health, Dr. Jamie Maguire of Tufts University, and Dr. Jeff Noebels of Baylor College of Medicine. The SAB, chaired by Professor Robert Langer, will focus on translation and clinical development strategies for Ovid's ROCK2 inhibitor and KCC2 direct activator portfolio.
Ovid anticipates multiple milestones in H2 2024, including a Phase 2 study of OV888/GV101, Phase 1 data readout for OV329, and IND submission for OV350.
Ovid Therapeutics announced the publication of preclinical studies in eNeuro, showcasing OV329's potential effectiveness in treating drug-resistant seizures. OV329, a next-gen GABA-AT inhibitor, demonstrated higher potency compared to vigabatrin, an FDA-approved GABA-AT inhibitor. Sustained exposure to OV329 in mice reduced GABA-AT activity and increased GABA levels in the brain, potentially offering robust and sustained seizure reduction. Additionally, OV329 reduced status epilepticus severity and prevented benzodiazepine resistance development in mice. These findings suggest OV329's differentiated profile and potential for better safety, dosing, and efficacy in refractory seizure treatment.
Ovid Therapeutics and Graviton Bioscience announced positive Phase 1 trial results for their OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM). The trial met its primary objective by demonstrating a favorable safety and tolerability profile, with no serious adverse events reported. Secondary endpoints showed target pharmacokinetic profiles were achieved, supporting once-daily dosing. The capsule was biologically active, producing dose-dependent pharmacodynamic effects. A Phase 2 study is planned for the second half of 2024. The findings indicate OV888/GV101 could be the first oral treatment for CCM, aiming to restore brain endothelial cell function, reduce inflammation, and prevent fibrosis.
Ovid Therapeutics reported on Takeda's Phase 3 study results for soticlestat, a treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The Skyline study in DS narrowly missed its primary endpoint but showed significant effects in secondary endpoints with p-values ≤ 0.008. The Skyway study in LGS missed its primary endpoint. Soticlestat had a favorable safety profile across both studies. Takeda will discuss the total data with regulatory authorities. Ovid highlighted its differentiated pipeline and financial strategy, with cash runway expected to last into H1 2026. Key upcoming milestones include Phase 2 and Phase 1 trials for OV888, OV329, and the KCC2 direct activator OV350.
FAQ
What is the current stock price of Ovid Therapeutics (OVID)?
What is the market cap of Ovid Therapeutics (OVID)?
